A team of researchers at Wistar’s Ellen and Ronald Caplan Cancer Center has identified a gene signature that accurately predicts the functioning of P53 variants—important for assessing cancer risk and optimizing choices for cancer therapeutics.
The Wistar Institute’s president and CEO, Dario C. Altieri, and his team have demonstrated the role of Parkin—a protein implicated in Parkinson’s disease—in the body’s innate immune response to cancer. Parkin is not expressed in several cancers. Altieri and his team engineered cancer cells to re-express Parkin and found that Parkin contributes to the production of interferons, which activate and attract T cells to fight the tumor. The lab’s findings were published in The Journal of Clinical Investigation.
